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Abstract 
High-grade epithelial ovarian carcinomas (OC) containing mutated BRCA1 or BRCA2 (BRCA1/2) 
homologous recombination (HR) genes are sensitive to platinum-based chemotherapy and 
poly(ADP-ribose) polymerase inhibitors (PARPi), while restoration of HR function due to 
secondary mutations in BRCA1/2 has been recognized as an important resistance mechanism. We 
sequenced core HR pathway genes in 12 pairs of pre-treatment and post-progression tumor biopsy 
samples collected from patients in ARIEL2 Part 1, a phase 2 study of the PARPi rucaparib as 
treatment for platinum-sensitive, relapsed OC. In six of 12 pre-treatment biopsies, a truncation 
mutation in BRCA1, RAD51C or RAD51D was identified. In five of six paired post-progression 
biopsies, one or more secondary mutations restored the open reading frame. Four distinct secondary 
mutations and spatial heterogeneity were observed for RAD51C. In vitro complementation assays 
and a patient-derived xenograft (PDX), as well as predictive molecular modeling, confirmed that 
resistance to rucaparib was associated with secondary mutations. 
 
Statement of Significance 
Analyses of primary and secondary mutations in RAD51C and RAD51D provide evidence for these 
primary mutations in conferring PARPi sensitivity and secondary mutations as a mechanism of 
acquired PARPi resistance. PARPi resistance due to secondary mutations underpins the need for 
early delivery of PARPi therapy and for combination strategies. 
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Introduction  
The hallmark of synthetic lethality is the requirement for two complementary hits that, while 
tolerated individually, result in cancer cell death when they occur together. A prime example is the 
observation that cells tolerate poly(ADP-ribose) polymerase (PARP) inhibition or homologous 
recombination (HR) impairment individually, but cancer cells with impaired HR are killed by 
PARP inhibitors (PARPis), reflecting drug-induced inhibition of PARP1 catalytic activity, trapping 
of PARP1 at sites of DNA damage, and/or alterations in the balance between error-free and error-
prone repair pathways (1-5). 
 
An exquisite proof of synthetic lethality comes from high-grade epithelial ovarian carcinomas (OC) 
with mutated BRCA1 or BRCA2 (BRCA1/2) that are sensitive to platinum-based chemotherapy and 
PARPi (6-9). Furthermore, somatic reversion mutations in either BRCA1/2 following exposure of 
OC to platinum-based chemotherapy or PARPi are identified as a mechanism of resistance. First 
reported in 2008 in a human pancreatic cell line and human OC (10,11), secondary mutations that 
restore the wild type BRCA2 open reading frame were detected in clinical OC, with a higher rate in 
women with platinum-resistant OC who had prior chemotherapy (12,13). More recently, 
examination of multiple tumor deposits at autopsy revealed additional evidence of BRCA2 reversion 
mutations and intra-patient heterogeneity with 12 distinct reversion events observed in a single 
patient with end-stage BRCA2-mutant OC who had received multiple chemotherapy regimens (14). 
To date, most of the secondary BRCA1/2 mutations are documented after platinum-chemotherapy 
exposure, with only limited reports after PARPi (15).  
 
Identification of patients with wild-type BRCA1/2 but HR-defective OC is important as these 
patients may potentially respond to PARPi therapy. Germline or somatic mutations in core HR 
genes beyond BRCA1/2, although individually rare, collectively occur in 7-8% of OC (16,17) and 
have been shown in vitro and in patients to underpin responses to PARPi (9,18). These mutations 
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are being increasingly identified in the clinic due to use of germline multiplex genetic testing and 
tumor sequencing (16,19). In addition to BRCA1/2, the RAD51 paralogues RAD51C and RAD51D 
are well established core HR pathway genes in which germline mutations increase ovarian cancer 
susceptibility (20-24). We recently reported that the PARPi rucaparib is active in OC with RAD51C 
or RAD51D mutations, with 3 partial responses (PR) and two cases of prolonged stable disease 
(SD) for 8.3 and 11.0 months duration among five evaluable patients treated with rucaparib (9). It is 
unknown if somatic reversion mutations are a mechanism of acquired resistance in cancers driven 
by mutations in HR genes beyond BRCA1/2.  
Here, we investigated whether secondary mutations in genes other than BRCA1/2 can arise as a 
mechanism of resistance post exposure to the PARPi rucaparib. 
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Results 
To study acquired PARPi resistance, we profiled pre-treatment tumor samples and post-progression 
biopsies from twelve patients with platinum-sensitive, relapsed high-grade epithelial OC treated 
with rucaparib in ARIEL2 Part 1. Samples were assessed using targeted next generation sequencing 
(NGS) with Foundation Medicine’s T5 assay, which sequences 287 cancer-related genes, including 
core HR pathway genes (Supplementary Fig. 1, Supplementary Table 1; ref. 9). In six of the 12 
cases, a deleterious mutation causing early protein termination in an HR pathway gene (four in 
BRCA1 and one each in RAD51C and RAD51D; five germline and one somatic mutation) was 
detected in either an archival tumor sample (n=6) and/or screening biopsy sample (n=4) prior to 
initiation of rucaparib treatment (Table 1). All six patients with HR pathway genes mutated in their 
OC derived clinical benefit from rucaparib (four with a confirmed RECIST PR and two with stable 
disease; PFS ranged from 9.6 to 22.0 months). In a seventh case, a somatic CDK12 mutation 
(c.264delC) was identified with no additional mutations detected in the post-progression biopsy. 
CDK12 has been reported to impact transcription of multiple HR genes, although is yet to be 
established as a core HR pathway gene (25, 26).   
 
In five of six cases with HR pathway gene mutations, post-progression biopsy samples contained at 
least one secondary mutation that was not detected in the pre-treatment carcinomas. These 
secondary mutations restored the open reading frame of the HR genes and thus potentially restored 
HR function and conferred resistance to rucaparib (Table 1). In case 2, the only case in which no 
secondary HR gene mutation was detected in the post-progression biopsy sample, the possibility of 
a reversion mutation to wild-type sequence was unlikely, because the wild-type allele frequency 
observed was not higher than  expected based on the estimated tumor purity. The secondary 
mutations detected in the BRCA1-mutated cases were large in-frame deletions (ranging from 123 to 
861bp) that restored the open reading frame either by deleting the primary frameshift mutation 
(cases 1 and 3), or by shifting the reading frame back into the correct state (case 4). The phasing of 
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primary and secondary mutations in case 4 could not be established with the Foundation Medicine’s 
T5 assay, since the secondary mutation (c.1835_1964del) was 80bp away from the primary 
mutation (c.2043dup); therefore, we performed colony PCR that confirmed cis configuration of 
these mutations (Supplementary Table 2, Supplementary Fig. 2). We have also detected another 
secondary mutation in the post-progression biopsy in case 4 that is a known slice site mutation 
(c.4096+1G>A) downstream of the primary frameshift mutation. mRNA analysis has previously 
shown that this variant results in a shortened BRCA1 isoform that lacks a large portion of exon 10, 
the BRCA1-Δ11q isoform, which would also splice out the primary mutation (27). This shortened 
isoform has been implicated as a potential mechanism of PARPi and platinum resistance (28). 
 
In case 5 with a germline RAD51C mutation (c.577C>T, p.R193*), a post-progression biopsy of an 
enlarging groin lymph node contained four distinct secondary mutations that all restored the open 
reading frame of RAD51C (Table 1, Fig. 1a-d). The functional capacity of the primary mutation and 
four identified secondary mutations were investigated in vitro using the OVCAR8 OC cell line. 
Firstly, CRISPR/Cas9-mediated knockout (KO) of RAD51C resulted in increased cisplatin and 
rucaparib sensitivity that could be reverted to the level of parental cell resistance by introduction of 
wild-type RAD51C cDNA (Fig. 1e, Supplementary Fig. 3). Conversely, introduction of RAD51C 
cDNA with the primary mutation failed to convey resistance, whereas RAD51C cDNA containing 
the secondary mutations did confer resistance to rucaparib, as well as to multiple other PARPi 
(olaparib, niraparib, talazoparib and veliparib) and platinum compounds (cisplatin and carboplatin) 
(Fig. 1e, Supplementary Fig. 3, and Supplementary Table 3).  
 
RAD51 foci formation assays confirmed proficient HR repair in cells complemented with wild-type 
RAD51C or any of the secondary RAD51C mutations tested, but not with the primary RAD51C 
mutation (Fig. 1f-g, Supplementary Fig. 4). Clear evidence for HR restoration was obtained using a 
standard HR reporter assay, in which a single genomic double-strand break is generated by the I-
 8 
 
SceI endonuclease to induce HR (Fig. 1h, Supplementary Fig. 5). RAD51C-/- MCF10A cells had 
substantially reduced HR repair compared to wild-type cells or RAD51C-/- cells expressing wild-
type RAD51C. While the RAD51C primary mutation R193* failed to complement the HR defect of 
RAD51C-/- cells, expression of all four RAD51C secondary mutants was able to restore HR 
comparable to wild-type RAD51C. We further demonstrated that RAD51C secondary mutants 
restore RAD51C R193* yeast-2-hybrid interactions with binding partners RAD51B and XRCC3 
(Fig. 1i and Supplementary Fig. 6). 
 
In order to assess the relative functional capacity of the RAD51C variants in vivo, a PDX was 
generated from the post-progression lymph node biopsy from case 5. Deep amplicon sequencing of 
RAD51C exon 4 was performed on two adjacent core biopsies of the lymph node, one of which had 
given rise to the PDX, and on tumors from three recipient-first passage (T1) mice (Fig. 2a). Whilst 
the first core contained all four RAD51C secondary mutations, only two of these were detected in 
the second core (Fig. 2b). Furthermore, microscopic spatial heterogeneity was observed between 
adjacent 40 µm sections within the second core (Supplementary Fig. 7). The portion of the second 
core biopsy used to generate the PDX predominately contained the c.574_577delinsGGCG 
mutation, as did PDX tumors from all three T1 mice, which had been implanted with tissue from 
the same core (Fig. 2a-b).  
 
To understand the context of the heterogeneity further, SNP array analysis (archival tissue and post-
progression biopsies) and whole-genome sequencing (WGS) of the post-progression biopsy and two 
T1 PDXs were performed. Copy number variation analysis revealed high levels of genomic 
instability in the archival sample and post-progression biopsies, with multiple amplifications and 
deletions detected throughout the genome. Little diversity was observed between the post-
progression core biopsy that gave rise to the PDX, and the PDX itself; the two T1 PDX analyzed 
were also highly concordant (Fig. 2c-d, Supplementary Table 4). Three copies of the RAD51C gene 
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were observed in both archival and post-progression biopsies, which was confirmed by FISH 
analysis of post-progression and PDX tissue (Fig. 2e).  
 
For case 6 with a germline RAD51D mutation (c.770_776del, p.G258Sfs*50), post-progression 
biopsy samples were collected from two different sites, a metastasis in the liver that was still 
responding to treatment and a growing metastasis in the spleen (Fig. 3a-c). The RAD51D secondary 
mutation (c.770_776delinsA) was found only in the splenic lesion that was progressing on 
rucaparib, suggesting that the detected secondary mutation conferred resistance (Table 1, Fig. 3d). 
To investigate the potential molecular basis of restored function observed with the RAD51D 
secondary mutation, we conducted molecular dynamics modeling of wild-type RAD51D, as well as 
RAD51D with both the primary and secondary mutations. Accurate simulation of the primary 
mutation was not possible because the frameshift-altered sequence diverged significantly from the 
sequence in the crystal structure. Molecular dynamics simulations indicated that in a DNA-
RAD51D homo-filament the S-G-R residues, which are replaced with lysine in the secondary 
mutation, were involved in dsDNA binding (Supplementary Fig. 8a-b and Supplementary Video); 
and modeling of the RAD51D with the secondary mutation indicated that the interaction with 
dsDNA was maintained (Supplementary Fig. 8c). Arginine to lysine substitutions are tolerated in 
evolutionary comparisons of this particular residue (Supplementary Fig. 8d), the interaction with 
dsDNA suggests that this secondary mutation can confer partial restoration of function. 
 
The functional capacity of the primary and secondary RAD51D mutations was further investigated 
in vitro using a previously described immortalized Chinese hamster (CHO) RAD51D KO cell line 
(29) and HR-competent human high-grade serous OC cell line PEO4 (containing functional 
BRCA2). Introduction of RAD51D cDNA with the secondary mutation (c.770_776delinsA) 
conferred resistance to cisplatin, rucaparib and other PARPis, while RAD51D cDNA containing the 
primary mutation did not (Fig. 3e, Supplementary Fig. 9). Two PEO4-derived clones, which 
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contained either a homozygous frameshift mutation (c.762_763del, p.D254Efs*72) in the same 
exon as the primary frameshift mutation, or the homozygous secondary mutation 
(c.770_776delinsA, p.S257_R259delinsK) in endogenous RAD51D, were generated using CRISPR 
homology-directed repair. PEO4 with the frameshift mutation had increased cisplatin and rucaparib 
sensitivity compared with parental PEO4 or the cells with the secondary mutation (Fig. 3f, 
Supplementary Fig. 10). Furthermore, RAD51 foci formation assay confirmed proficient HR repair 
in parental PEO4 and cells expressing the secondary mutation, but not in cells with the frameshift 
mutation (Fig. 3g).  
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Discussion 
In order to understand the development of secondary resistance to PARPi therapy, we analysed 12 
cases in which paired tumor biopsies were obtained both before treatment and following tumor 
progression, from patients with high-grade OC receiving the PARPi rucaparib on the ARIEL2 Part 
1 trial. Six of twelve cases were found to contain mutations in one of three DNA repair genes, 
BRCA1, RAD51C or RAD51D, prior to therapy. Strikingly, in five of these six cases at progression 
we identified secondary mutations that restored the open reading frame by next-generation 
sequencing of progressing lesions, including two cases that had two or more secondary mutations. 
In a seventh case, we detected a somatic frameshift mutation in CDK12, a reported regulator of HR, 
although no secondary mutations were observed in the progressing lesion. 
 
Since secondary mutations in RAD51C and RAD51D have not been previously described in 
preclinical or clinical studies, we focused in detail on those mutations. Four distinct RAD51C 
secondary mutations were identified within one core biopsy, highlighting the selective pressure for 
the tumor cells to restore HR repair in the face of PARPi treatment. The observed microscopic 
spatial heterogeneity in the relapsed lymph node extends a previous report by Patch et al. (14), 
where 12 distinct secondary BRCA2 events were detected within one autopsy case, including five 
events, each identified at more than one metastatic site.  
 
Functional analyses demonstrated that the RAD51C cDNA with the secondary mutations were able 
to restore RAD51C function in RAD51C KO ovarian cancer cells, as evidenced by increased 
homologous recombination, restored ability to bind the RAD51C binding partners RAD51B and 
XRCC3, and increased resistance to platinum and PARP inhibitors. Based on the observed variant 
frequencies reported for this case, including FISH and WGS analyses, we predict that each primary 
cancer cell contained three copies of the primary RAD51C mutation, whereas each cell with 
acquired resistance contained two copies of the primary mutation and one of four possible 
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secondary mutations (Supplementary Fig. 11). We generated a PDX from the post-progression 
biopsy containing the RAD51C secondary mutations. However, with only one secondary mutation 
predominant in the biopsy material from which the PDX was generated and in the PDX itself, it was 
not possible to detect relative functional selection of the four secondary RAD51C mutations present 
in that lymph node under rucaparib pressure in vivo.  
 
Molecular dynamics modeling of the RAD51D species with the secondary mutation revealed that 
Ser257-Gly258-Arg259 to Lys substitution maintains the interaction with dsDNA, which was 
observed in the wild type RAD51D model. This was further supported by the presence of lysine at 
codon 259 in non-human RAD51D, suggesting that this secondary mutation could confer partial or 
full restoration of function. In vitro functional analyses of the primary and secondary RAD51D 
mutations provided additional evidence that the primary mutation sensitized cells to platinum and 
PARPi compounds, whilst the secondary mutation conferred resistance to both. 
 
These observations provide evidence for restoration of functional HR under PARPi selection 
pressure in tumors with RAD51C or RAD51D mutations, supporting the view that mutations in 
these genes are synthetically lethal with PARP inhibition and demonstrating that secondary 
mutations are an important clinical mechanism of resistance in non-BRCA1/2 HR genes. Moreover, 
we observed secondary mutations at progression following PARPi therapy in five of six cases 
containing a primary mutation in a DNA repair gene at diagnosis. Collectively, these results 
identify the need for sequencing PARPi therapy early during a patient’s disease course and 
highlight the urgent need for development of PARPi-containing combination or sequencing 
strategies capable of more robust cell killing, in order to circumvent or delay the development of 
PARPi resistance 
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In summary, in vitro and in vivo analyses of primary and secondary mutations in RAD51C and 
RAD51D provided evidence for secondary mutations restoring most of the open reading frame 
beyond the primary mutation, thereby re-instituting HR function and contributing to development of 
clinical resistance to the PARPi rucaparib. Furthermore, these data support the role of primary 
mutations of RAD51C and RAD51D in conferring PARP inhibitor sensitivity and reveal secondary 
mutations in these genes as a mechanism of acquired PARPi resistance.  
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Methods 
Patient samples 
Archival tumor and a tumor deposit suitable for attempted pre-treatment biopsy were required for 
all patients who enrolled in the ARIEL2 Part 1 trial (NCT01891344). A post-progression tumor 
biopsy was optional. RECIST imaging & CA-125 level monitoring was recorded for the duration of 
patients’ enrolment in the trial. 
 
Cell lines and Culture 
The human ovarian carcinoma cell line OVCAR8 was obtained from National Cancer Institute 
(Rockville, MD). Early passages of the parental OVCAR8 and RAD51C KO 2-130 were banked, 
tested for Mycoplasma and STR profiled; subsequent thaws were used within 6 months. The PEO4 
cell line was obtained from F. Couch, Mayo Clinic in 2013 and viably stored until 2016; subsequent 
thaws were used within 6 months. The PEO4 cells were routinely tested for Mycoplasma and were 
last authenticated by STR profiling in April 2017. The CHO cell lines parental and deficient for 
RAD51D were obtained from Drs. Larry Thompson and Claudia Wiese, tested for Mycoplasma, and 
passaged for 2 months. The MCF10A cells were provided by B.H. Park (John Hopkins University 
School of Medicine). Early passage cells obtained were integrated with DR-GFP reporter and 
viably stored; subsequent thaws were used within 4 months. These modified cells were used for 
generating RAD51C conditional mutants and subsequent experiments. RAD51C conditional 
MCF10A cell line was tested negative for Mycoplasma on May 10th, 2017 using the MycoAlert 
PLUS assay kit from Lonza. 
 
The OVCAR8 cell line was cultured in RPMI 1640 (Corning) supplemented with 10% fetal bovine 
serum (Peak Serum) and 1% penicillin and streptomycin (Corning) in a 5% CO2 atmosphere at 
37oC. The CHO cell line was cultured in MEM alpha (Corning) with 10% FBS (Peak) and 1% P/S 
(Corning) in 5% CO2 at 37 oC. The PEO4 and OVCAR8 cell lines (for RAD51 foci formation 
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assays) were cultured in DMEM/F-12, GlutaMAX™ Supplement medium (Gibco™) containing 5 
μg/ml insulin, 50 ng/ml EGF and 1 µg/ml hydrocortisone in a 5% CO2 atmosphere at 37oC.  The 
MCF10A cell line was cultured in DMEM HG/F-12 supplemented with 5% horse serum, 1% 
penicillin and streptomycin, 100 ng/ml cholera toxin, 20 ng/ml epidermal growth factor, 0.01 mg/ml 
insulin and 500 ng/ml hydrocortisone in a 5% CO2 atmosphere at 37 oC.  
 
Compounds 
Rucaparib camsylate salt was manufactured by Lonza (Basel, Switzerland). Carboplatin, cisplatin, 
olaparib, niraparib, talazoparib, and veliparib were obtained from MedChem Express. 
 
Generation of OVCAR8 KO (clone 2-130) and overexpressing cell lines 
To generate OVCAR8 KO (clone 2-130), OVCAR8 cells were seeded at 0.2 × 106 cells per well in 
6-well plates on day 1 in complete media. On day 2, cells were transfected with Fugene 6 
(Promega) according to the manufacturer’s recommendation with 1 µg RAD51C CRISPR plasmid 
(Santa Cruz Biotechnology). Transfected cells were selected with 2 µg/ml puromycin (Thermo 
Fisher Scientific). Cells were single cell cloned by limiting dilution, and expanded in complete 
media without puromycin. RAD51C KO was confirmed by genomic DNA sequencing. DNA was 
isolated using PureLink Genomic DNA mini kit (Thermo Fisher Scientific), and PCR was 
performed using KOD Hot Start Master Mix (EMD Millipore) with the follow primers: forward 
primer 5’-gcagaagccttagaaactctgc and reverse primer 5’-tgaataacgcagaaacttcctg, according to the 
manufacturer’s recommendation. The PCR product was purified using a QIAquick PCR 
Purification kit (Qiagen) and Sanger sequencing was performed with primer 5’-
tttcattaagggcactccacc. RAD51C clone 2-130 sequences showed 35 bp deletion RAD51C c.231_264 
that generated nonsense mutation p.E80*. 
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To generate cells that transiently express wild-type and mutated RAD51C for RAD51 foci analysis, 
cells were transfected with commercially obtained, mutated RAD51C pcDNA3.1(+)/Hygro 
plasmids (OHu21400C, GenScript) using Lipofectamine™ 3000 Reagent (Thermo Fisher 
Scientific), following manufacturer’s instructions. After 48 hour recovery period transfected cells 
were selected with 200 µg/ml hygromycin (Thermo Fisher Scientific). To generate stable 
overexpressing RAD51C mutants, gene fragments containing specific mutations were synthesized 
(Integrated DNA Technologies) and cloned into the lentivector encoding RAD51C open reading 
frame under the control of the PGK promoter (Genecopoeia). Lentivirus vectors were packaged in 
HEK293 cells with 3rd generation lentiviral system (System Biosciences), and RAD51C 2-130 cells 
were transduced with 15 MOI plus polybrene 8 µg/ml for 24 hours. Cells were cultured in complete 
media for 48 hours before puromycin selection. 
 
Generation of mutant RAD51D overexpressing CHO RAD51D KO cell lines 
To generate stable overexpressing RAD51D mutants, gene fragments containing specific mutations 
were synthesized (Integrated DNA Technologies) and cloned into the lentivector encoding RAD51D 
open reading frame (NM_002878.3) under the control of the PGK promoter (Genecopoeia). 
Lentivirus vectors were packaged in HEK293 cells with 3rd generation lentiviral system (System 
Biosciences), and CHO RAD51D KO cells (29) were transduced with 15 MOI plus polybrene 8 
µg/ml for 24 hours. Cells were cultured in complete media for 48 hours before puromycin selection. 
 
Generation of PEO4 cell line with the secondary RAD51D mutation 
To generate PEO4 cells with the secondary RAD51D mutation (c.770_776delinsA), PEO4 cells 
were transduced with lentiviral Cas9 vector (PUCas9Cherry) and doxycycline-inducible CRISPR 
guide with GFP vector (FgH1tUTG) with CRISPR guide 5’-CAACCACATAACTCGAGACA 
(30). 40 pmol of ssODN containing the secondary mutation and a silent PAM mutation with 80 bp 
sequence overlap on each side (IDT) was transfected using Lipofectamine™ 3000 Reagent (Thermo 
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Fisher Scientific), following the manufacturer’s instructions. After overnight incubation, CRISPR 
guide was activated by doxycycline-supplemented medium (1µg/ml) for 3 days. mCherry and GFP 
double-positive cells were single-cell plated using flow cytometry. After expanding for at least two 
weeks, single cell colonies were sequenced for the presence of homozygous secondary mutation 
using MiSeq platform. The colony with the frameshift RAD51D mutation (c.762_763del, 
p.D254Efs*72) was also selected from this process. 
 
RAD51 foci formation assay 
Cells were treated with DMSO or 10 µM rucaparib for 24, 48 or 72 hours. Cells were fixed with 
either 4% paraformaldehyde or methanol, permeabilised with 0.2% TritonX-100, blocked with 
blocking buffer (1% BSA, 2% FCS or 1% BSA, 3% milk, 2% goat serum in PBS) and incubated 
with rabbit anti-RAD51 (Abcam) and either mouse anti-Geminin (Abcam) or mouse anti-H2AX 
(Abcam) antibodies. For RAD51 foci formation with geminin staining, anti-rabbit 647 and anti-
mouse 546 Alexa Fluor® secondary antibodies (Invitrogen, Molecular Probes™) were used. Nuclei 
were counterstained with Hoechst 33342 (NucBlue® Live ReadyProbes® Reagent; Thermofisher 
Scientific). Cells were imaged using a LSM 780 inverse laser scanning microscope (Zeiss) and 
captured with a LSM T-PMT detector (Zeiss). At least 194 cells from 4 fields of view and 2 
independent experiments were counted. Cells with ≥5 RAD51 foci/nucleus were scored using 
CellProfiler (version 2.2.0, Broad Institute). For RAD51 and H2AX foci formation assay, anti-
rabbit 488 and anti-mouse 594 Alexa Fluor® secondary antibodies (Invitrogen, Molecular Probes™) 
were used. Nuclei were counterstained with DAPI (Sigma). Cells were imaged using Leica DM 
1000 LED at 40x.  
 
Cell Viability Assays 
Endpoint viability assays were performed using the CellTitre-Glo (Promega) assay according to the 
manufacturer’s protocol. Briefly, cells were seeded at 600-800 cells per in 384-well plates or 2000 
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cells in 96-well plates, and allowed to establish overnight before adding treatments. Cells were 
treated for 6-7 days with compounds, over a range of concentrations, then assay was terminated and 
viability assessed using luminescence detection on a Victor X4 plate reader (Perkin Elmer). 
Luminescence was normalized to DMSO control, and IC50 values were calculated using a sigmoidal 
dose-response curve fit analysis (Prism software, GraphPad).  
 
HR reporter assay 
The DR-GFP reporter was introduced into MCF10A cells as previously described (31). Cre 
recombinase was expressed in conditional RAD51C-/- MCF10A cells to remove an ectopic floxed 
RAD51C gene (R.P. and M.J., unpublished) and in isogenic wild-type cells as a control. Post-Cre 
expression, cells were infected with an I-SceI-expressing lentivirus. GFP+ cells were measured by 
flow cytometry (BD FACScan) 48 hours after infection and data were analyzed using FlowJo 
software. Without I-SceI expression the number of GFP+ cells was ≤0.01.  
 
Creation of Y2H and pWZL expression vectors 
The RAD51C mutants were generated in the yeast-two-hybrid (Y2H) plasmids (pGAD-C1 and 
pGBD-C1) and pWZL plasmid using site-directed mutagenesis (Supplementary Table 5). RAD51C 
and RAD51B cDNA were sub-cloned into the pGAD-C1 and pGBD-C1 vectors using 5'-EcoRI and 
3'-SalI restriction sites. The RAD51C and RAD51B cDNA was a gift from Jun Huang (32) and the 
pGAD-XRCC3 and pGBT-XRCC3 plasmids were a gift from David Schild (33).  
 
Y2H assay 
The yeast-2-hybrid experiments were performed as previously described (34), except that the 
indicated GAL4 activating domain- and binding domain-expressing vectors were co-transformed 
into the YPJ694a yeast strain. 
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BRCA1 colony PCR 
10 ng genomic DNA from post-progression biopsy (case 4) was PCR amplified with primers: 
forward 5’-gcatgtcgacGGGAACTAACCAAACGGAGCA and reverse 
5’atgcaagcttGAGATCTTTGGGG-TCTTCAGCA.  Primers were designed with restriction sites for 
Sal1 and HindIII.  Reaction was performed with KOD polymerase (EMD Millipore) according to 
manufacturer’s recommendation, and cleaned by QIAquick PCR kit (Qiagen).  pUC19 (NEB) and 
PCR product were cut with Sal1 (NEB) and HindIII (NEB), and cleaned by QIAquick PCR kit, 
before ligating with T4 ligase (NEB) and transforming E. coli bacteria.  Colonies were amplified by 
rolling circle amplification using bacteriophage phi29 DNA polymerase (NEB), before Sanger 
sequencing with M13 Forward-20 primer. 
 
Western Blotting – OVCAR8, CHO and PEO4 
Whole cell lysates were prepared using RIPA buffer (Sigma) containing protease inhibitor cocktail 
and protein concentration was assessed by BCA colourmetric protein determination (Pierce). Equal 
protein loads were resolved on precast 4–12% Bis-Tris gels under reducing conditions. Protein was 
transferred to nitrocellulose membranes using iBlot dry transfer method (Invitrogen), then probed 
with primary antibody anti-RAD51C (Santa Cruz Biotechnology), anti-RAD51D n-terminal 
(Abcam), anti-RAD51D c-terminal (Santa Cruz Bio),  anti-GAPDH (Cell Signaling), anti-tubulin 
(Cell Signaling) or anti-actin (Abcam) followed by peroxidase-labelled secondary antibody and 
visualised by enhanced chemiluminescence (SuperSignal Chemiluminescent Substrate; Thermo 
Scientific) or IRDye-labelled secondary antibody (LI-COR Biotechnology) according to the 
manufacturer’s instructions. Band volume analysis was conducted using Odyssey Fc (LI-COR 
Biotechnology). 
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Western Blotting – MCF10A (subcellular) 
Nuclear extracts were collected from MCF10A cells using the cytoplasmic lysis buffer (10 mM 
Tris-HCl, 0.34 M sucrose, 3 mM CaCl2, 2 mM Magnesium acetate, 0.1 mM EDTA, 0.5% NP-40, 
protease inhibitor) and nuclear lysis buffer, (20 mM HEPES, 3 mM EDTA, 10% glycerol, 150 mM 
potassium acetate, 1.5 mM MgCl2, 0.1% NP-40, protease inhibitor). 30 µg of nuclear protein was 
used for detection. Protein was separated on 10% acrylamide gels and transferred to PVDF 
membranes, and protein was detected on a LiCor CLX scanner. RAD51C expression was detected 
with RAD51C antibody (ab55728 1:500; Abcam), and equal nuclear loading was detected using 
PCNA antibody (sc-56 1:250; SantaCruz), and IR dye secondary antibodies from LiCor 
Biosciences. The image was adjusted for brightness and contrast using Photoshop (Adobe Systems 
Incorporated). 
 
Western Blotting –Y2H 
Yeast expressing the indicated AD and BD constructs were grown overnight at 30˚C in 5 ml YPD 
and then diluted to 0.2 OD600 in YPD for 90 minutes. Whole cell lysates of equal cell numbers (0.2 
OD600) was extracted by TCA precipitation. Protein was separated on 10% acrylamide gels and 
transferred to PVDF membranes, and protein was detected on a LiCor CLX scanner. RAD51C 
expression was detected with RAD51C antibody (ab55728 1:500; Abcam), equal loading was 
detected using a Kar2 antibody (sc-33630 1:2000; Santa Cruz), and IR dye secondary antibodies 
(1:20,000) from LiCor Biosciences. The image was adjusted for brightness and contrast using 
Photoshop (Adobe Systems Incorporated). 
 
Generation and treatment of patient-derived xenografts (PDX) 
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All experiments involving animals was approved by the Walter and Eliza Hall Institute of Medical 
Research Animal Ethics Committee. A patient-derived xenograft (PDX) was generated from the 
post-progression lymph node biopsy by transplanting fresh fragments subcutaneously into six 
NOD/SCID IL2Rγnull recipient mice (T1 – passage 1; ref. 35), three of which developed tumors.  
The PDX tumors generated were transplanted into recipient mice (T2 – passage 2), minced and 
cryopreserved in DMSO and snap frozen for further analysis. A mouse harboring T2 PDX tumor 
was treated with 450 mg/kg rucaparib for 2 weeks (oral gavage once daily Monday-Friday) at ~0.1 
cm3 in size. The tumor was harvested and snap frozen 24 hours after treatment completion. DNA 
was extracted from the archival tumor sample and from the post-progression biopsy for sequencing 
analysis. SNP array analysis was performed on archival tissue and the post-progression biopsy and 
WGS was performed on the post-progression biopsy and two T1 PDXs. 
 
Serial Section Analysis 
A small fragment of one of the snap-frozen post-progression biopsy cores from patient 5 with the 
germline RAD51C mutation was embedded in Tissue-Tek® O.C.T. compound (Sakura Finetek). Six 
serial sections were collected (40 µm each) with a 4 µm section cut for H&E staining in between 
each section. Direct PCR was performed on each serial section using Phusion Human Specimen 
Direct PCR Kit (Thermo Scientific™) following manufacturer’s instructions. Briefly, 25 µl of 
buffer and 0.5 µl of DNA release reagent was added to each tube with section scrolls and incubated 
at 98C for 2 mins. Amplicon libraries were prepared using a two-step PCR approach: first internal 
PCR to amplify the region of interest (5’-tcgtcggcagcgtcagatgtgtataagagacag-tccaaaggagaacattttgtta 
forward primer and 5’-gtctcgtgggctcggagatgtgtataagagacag-tgtgtagtcacgacagcgaaa reverse primer), 
followed by second outer PCR to add the sequencing adaptors and indexes for multiplexing). 
Briefly, 2 μl of digested section sample for first PCR or inner product for second PCR was added to 
5 μl of 5 × Q5 Reaction buffer (NEB), 1 μl of each primer (forward and reverse; 2nM each) for first 
PCR or 1 µl of each Nextera XT index (unique i5 and i7, Illumina), 0.5 μl of dNTPs (10 mM each), 
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0.25 μl of Q5 Hot Start High-Fidelity DNA Polymerase (NEB), and 15.25 µl of dH2O. The PCR 
was performed as follows: 30 seconds at 98 °C for initial denaturation, followed by 20 cycles of 10 
seconds at 98 °C, 15 seconds at 60 °C for first PCR or 63°C for second PCR, and 20 seconds at 72 
°C, followed 2 minutes at 72 °C for final extension. The libraries were cleaned using standard 
Agencourt AmpureXP beads (Beckman Coulter) procedure with DNA to bead ratio of 1:0.9, and 
normalised to 1 nM concentration (using the Qubit dsDNA HS Assay Kit for quantification). 
Libraries were sequenced using MiSeq Nano v2 300-cycle kit (Illumina) at 10 pM final 
concentration to a minimum depth of 30,000x. Reads were aligned using bwa-mem to the Human 
GRCh38, and visualized for further analysis using IGV browser (36). 
 
Genomic analysis 
All tumors were sequenced using Foundation Medicine’s NGS-based assay (19). Analysed data 
were plotted using OncoPrint. Germline HRR gene mutations were confirmed by sequencing of 
DNA extracted from blood using the NGS-based BROCA assay (37).  
Whole-genome sequencing libraries were prepared for a post-progression biopsy of patient 5 and 
the two first-passage PDX tumors generated from this biopsy. The libraries were prepared using the 
TruSeq Nano library preparation kit (Illumina), and the sequencing was performed on the Illumina 
X Ten platform (Kinghorn Centre for Clinical Genomics, Darlinghurst). 
Adaptor sequences were removed with Trimmomatic 0.36 (38) before mapping to the Human 
GRCh38 (GCA_000001405.15) and Mouse GRCm38(GCF_000001635.25) genomes with Bowtie2 
2.2.5 (39).  Human reads were separated from mouse background with Xenomapper (40).  Reads 
were sorted and indexed with Samtools 1.3.1 (41).  Copy number analysis was performed with 
HMMcopy 1.16 (42) and plotted with CIRCOS 0.67 (43). Coriell Cell Repository NA12878 
reference cell line DNA previously processed with the TruSeq Nano kit at KCCG was used an 
unrelated normal control. 
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High-depth amplicon analysis of RAD51C exon 4 was performed on the multiple samples from 
patient 5 with germline RAD51C mutation (pre-treatment biopsy, post-progression biopsy and 4 
PDX tumors) in triplicate. DNA was extracted using QIAamp DNA mini kit (QIAGEN). Amplicon 
libraries were prepared using a two-step PCR approach, as described for serial section analysis, 
with 20 ng DNA input in the first PCR. The PCR was performed as follows: 30 seconds at 98 °C 
for initial denaturation, followed by 16 cycles for first PCR or 12 cycles for second PCR of 10 
seconds at 98 °C, 15 seconds at 60 °C for first PCR or 63°C for second PCR, and 20 seconds at 72 
°C, followed 2 minutes at 72 °C for final extension. The libraries were cleaned and sequenced as 
described for serial section analysis to a minimum depth of 10,000x. Reads were aligned using bwa-
mem to the Human GRCh38, and visualized for further analysis using IGV browser (36). 
 
RAD51C FISH 
Frozen OCT sections from the post-progression biopsy (Core 2 OCT block for serial sectioning) 
and the PDX sample treated with 450 mg/kg for 2 weeks, both from patient 5 with the germline 
RAD51C mutation, as well as an unrelated control PDX were thawed, fixed in 4% PFA and pre-
treated with SPOT-Light® Tissue Pre-treatment kit (Invitrogen). Briefly, sections were incubated in 
pre-treatment solution for 15 minutes at 95°C, washed in PBS and incubated with enzyme for 10 
minutes at room temperature. Sections were dehydrated, incubated with denaturation buffer (70% 
formamide, 2x SSC, pH 7.0-8.0) for 5 minutes at 73°C, dehydrated, and incubated with prepared 
RAD51C probe (as per manufacturer’s instructions; Empire Genomics) for 24 hours at 37°C. 
Sections were then washed with WS1 (0.4X SSC/0.3% NP40) for 2 minutes at 73°C, followed by a 
wash with WS2 (2X SSC/0.1% NP40) for 1 minute at room temperature. Nuclei were 
counterstained with Hoechst 33342 (NucBlue® Live ReadyProbes® Reagent; Thermofisher 
Scientific) and coverslipped with fluoromount G (SouthernBiotech). Sections were imaged using a 
LSM 780 inverse laser scanning microscope (Zeiss) and captured with a LSM T-PMT detector 
(Zeiss).  
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Molecular Dynamics Modeling 
Molecular models were made of RAD51D to test the effects of deletions and mutations using 
NAMD (44).  Initial models were constructed from primary sequence using the Swiss-Model web 
Server (45), which constructed a model using the Saccharomyces cerevisiae 1SZP pdb structure as a 
template (46). The model was constructed as a 6 monomer helical complex with an additional 58 
base pair double stranded DNA loosely positioned along the central helical axis. A homomeric 
model was constructed as appropriate crystal structures were not available to allow modeling of the 
heteromeric RAD51B/C/D and XRCC2 complex. This model provides general information on 
interaction between the sub-units and between the protein and DNA.  RAD51 paralogues and RecA 
have been shown to bind both ssDNA in an ATP catalyzed reaction and dsDNA in a filament 
structure.  As a computational simplification, we chose to model only the interaction with dsDNA. 
A wild-type and two mutant models were constructed (p.Ser257_Arg259delinsLys and 
p.Ser257_Arg259fs*50, see Fig. 3d for annotation) using VMD (47) and the psfgen module.   All 
models were solvated and ionized with sodium chloride to approximately 0.15M and electrical 
neutrality. The initial dimensions of the wild-type system were 108×108×200 Angstroms, with a 
total of 222339 atoms for the WT, and 230572 or 226326 atoms for the primary and secondary 
mutants, respectively. Each model was equilibrated for 1 nanosecond before performing production 
runs.  Production runs were performed using NAMD 2.10 at 310K using a NPT ensemble (Constant 
pressure and temperature).  Long-range Coulomb forces were computed with the Particle Mesh 
Ewald method with a grid spacing of 1 Å. 2 fs timesteps were used with non-bonded interactions 
calculated every 2 fs and full electrostatics every 4 fs while hydrogens were constrained with the 
SHAKE algorithm. The cut-off distance was 12 Å with a switching distance of 10 Å and a pair-list 
distance of 14 Å. Pressure was controlled to 1 atmosphere using the Nosé-Hoover Langevin piston 
method employing a piston period of 100 fs and a piston decay of 50 fs. Trajectory frames were 
captured every 100 picoseconds.  Simulation trajectories were viewed with VMD (47).  
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Table Legends  
Table 1. Clinical and molecular features of twelve OC cases with post-progression biopsies. 
The number of prior chemotherapeutic regimens, best response to treatment on ARIEL2 Part 1, 
progression free survival (PFS) on ARIEL2 Part 1 and details of the mutations detected in known 
Homologous Recombination (HR) DNA repair genes are shown. Seven of twelve cases were found 
to contain a mutation in either an HR gene (BRCA1 or RAD51C/D) or a gene that impacts 
transcription of multiple HR genes (CDK12), five of which contained secondary mutations in the 
post-progression biopsy. For five cases, no HR or related gene mutation was observed in archival, 
pre-treatment or post-progression tumor material. Secondary mutations were only identified in post-
progression cases with HR gene mutations (p=0.015, Fisher’s exact). Number of prior regimens, 
best response by RECIST/GCIG CA-125 criteria. RECIST, CA-125, and PFS data based on the 
data cut-off date of April 29, 2016. LOH status was determined from variant allele frequency. 
Transcripts used for variant annotation: BRCA1, NM_007294.3; RAD51C, NM_058216.2; 
RAD51D, NM_002878.3; and CDK12, NM_016507.3. CA-125 not evaluable (NE); germline 
mutation (GL); somatic mutation (SOM); secondary mutation (2º MUT); loss of heterozygosity 
(LOH). # Tumor purity was estimated based on the genome-wide copy number analysis by 
Foundation Medicine. ^The reported RAD51C mutation frequencies were estimated from biopsy 
core 1 using Foundation Medicine’s T5 assay. To investigate tumor heterogeneity in more detail 
this sample was sequenced using a single amplicon assay (see Fig. 2). †RAD51D secondary 
mutation was only detected in the non-responding splenic lesion, while only the primary mutation 
was detected in the responding liver lesion (see Supp. Table 1). 
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Figure Legends 
 
Figure 1. Identification and functional assessment of RAD51C secondary mutations identified 
in the post-progression biopsy in case 5. a, RECIST measurements of three metastatic sites, 
which were monitored in the patient identified to have a germline RAD51C mutation (c.577C>T). 
None of these lesions progressed during rucaparib treatment. After 11 months of rucaparib 
treatment the patient developed a new enlarged groin lymph node, which was biopsied. b, Serum 
CA-125 levels monitored during the ARIEL2 Part 1 trial in the patient with the germline RAD51C 
mutation (c.577C>T). c, CT scans prior to, during, and following treatment of the patient with the 
germline RAD51C mutation (c.577C>T). d, Diagram of the predicted RAD51C protein sequence 
changes caused by the primary (c.577C>T) and the secondary mutations (c.577_579delinsTGG, 
c.577C>A, c.574_577delinsGGCG, c.577_578delinsTT) detected in the progressing groin lymph 
node biopsy from the patient with the germline RAD51C mutation (c.577C>T). Examination of the 
parental OVCAR8, OVCAR8 RAD51C KO clone 2-130 and OVCAR8 RAD51C KO clone 2-130 
transduced with wild-type (WT), primary or secondary mutant RAD51C transcripts using: e, Cell 
viability assay after treatment with rucaparib for 6 days and f,  γH2AX and RAD51 foci formation 
48 h post rucaparib (10 µM) exposure: γH2AX foci are observed at the sites of DNA damage, and 
RAD51 foci are observed at the sites of HR pathway repair. g, Quantification of RAD51 foci 
formation in geminin positive cells (Mean ± SEM). OVCAR8 RAD51C KO cells were transfected 
with plasmids expressing the WT, primary or secondary mutant RAD51C transcripts. The response 
of these cells to 10 µM rucaparib was compared after 48 hr to parental OVCAR8 cell line or 
OVCAR8 RAD51C KO clone. n=8 (4 fields of view from 2 independent experiments) for each cell 
type and treatment. ***, p<0.001. h, RAD51C secondary mutants restore HR as well as WT 
RAD51C in RAD51C-mutant cells. RAD51C-/- MCF10A cells containing the DR-GFP reporter were 
infected with an I-SceI expressing lentivirus and cultured for 48 hours. GFP+ cells were quantified 
by flow cytometry. n≥4 independent experiments. ***, p<0.001. i, RAD51C secondary mutants 
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restore RAD51C-R193* yeast-2-hybrid (Y2H) interactions with RAD51C binding partners 
RAD51B and XRCC3. RAD51C and the corresponding mutants were cloned into the yeast-2-hybrid 
(Y2H) plasmids expressing the GAL4 activating domain (AD) whereas RAD51B and XRCC3 were 
cloned into GAL4 binding domain (BD) expressing plasmids. Empty AD and BD vectors were used 
as negative controls. A Y2H interaction was observed as growth on medium lacking histidine, 
leucine, and tryptophan (Interaction), whereas equal cell loading was observed on medium lacking 
leucine and tryptophan (Control). PD, progressive disease; PR, partial response. 
 
Figure 2. Tumor heterogeneity analysis of the post-progression biopsy with secondary 
RAD51C mutations. a, Model of the post-progression groin lymph node biopsy cores collected for 
analysis. Two post-progression core biopsies of the enlarging lymph node were obtained. Core 1 
was used for genomic DNA analysis. Two ends of core 2, annotated as sections 1 and 2, were used 
for separate DNA extractions and subsequent analysis. The middle section of the core 2 was used to 
generate PDX, where 6 small pieces were subcutaneously transplanted into the recipient mice. The 
left-over section of core 2 adjacent to the section 1 was frozen in OCT and then sectioned for direct 
PCR library preparation. b, Variant allele frequencies detected by sequencing in the pre-treatment 
and post-progression biopsies, and in the generated PDX samples. Deep amplicon sequencing of 
RAD51C exon 4 (minimum coverage of 10,000x) was performed on these cores and on three 
recipient first passage (T1) mice. Whilst the first core analyzed contained all four RAD51C 
secondary mutations, only two of these were detected in the second core, which was used to 
generate the PDX. Spatial heterogeneity was even observed within the second core biopsy, with the 
c.577C>A mutation evident on one side of the core biopsy and at decreasing frequency towards the 
center of the core. The other side of the core biopsy predominately contained the 
c.574_577delinsGGCG mutation, as did PDX tumors expanded in three T1 mice implanted with 
tissue from the same core. PDX T2 was treated with 450mg/kg rucaparib for 2 weeks. c, Circos plot 
of the copy number alterations detected by WGS in the post-progression biopsy (Core 2 Section 2) 
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showing high levels of genomic instability. Losses are depicted in red, and gains in blue. d, Circos 
plot of copy number alterations detected by WGS in the two analyzed PDX tumor samples obtained 
from the post-progression biopsy (Core 2 Section 2). The outer and inner copy number tracks show 
the two analyzed tumor samples, while the middle track shows differences between them. e, 
RAD51C FISH assay of the post-progression biopsy (Core 2 OCT block for serial sectioning) and 
the PDX sample treated with 450mg/kg for 2 weeks. Arrows point to the cells with three distinct 
signals visible for the post-progression biopsy and the PDX sample. 
 
Figure 3. Identification and functional assessment of RAD51D secondary mutation identified 
in the post-progression biopsy in case 6. a, RECIST measurements of three tumor deposits in the 
patient with a germline RAD51D mutation (c.770_776del). The metastasis in the left lobe of the 
liver was biopsied prior to treatment. Surgery was performed following progression on rucaparib, in 
order to remove the enlarging splenic lesion. The tumor deposit in the liver, which was still 
responding to rucaparib treatment, was also excised. b, Serum CA-125 levels monitored during the 
ARIEL2 Part 1 trial in the patient with the germline RAD51D mutation (c.770_776del). c, 
Computed tomography (CT) images obtained prior to, during and following treatment of the patient 
with the germline RAD51D mutation (c.770_776del). d, Diagram of the predicted RAD51D protein 
sequence changes caused by the primary (c.770_776del) and the secondary mutation 
(c.770_776delinsA) detected in the patient with the germline RAD51D mutation. e, In vitro 
response to rucaparib in parental CHO cell line, CHO RAD51D KO clone and CHO RAD51D KO 
clone transduced with WT, primary or secondary mutant RAD51D transcripts after treatment for 6 
days. f, In vitro response to rucaparib in parental PEO4 cell line, PEO4 cells with the homozygous 
frameshift RAD51D mutation (c.762_763del) and PEO4 cells with the homozygous secondary 
RAD51D mutation (c.770_776delinsA) after treatment for 7 days. g, RAD51 foci formation 48 h 
post rucaparib (10 µM) exposure in geminin positive cells in parental PEO4, PEO4 cells with the 
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homozygous frameshift RAD51D mutation (c.762_763del) and PEO4 cells with the homozygous 
secondary RAD51D mutation (c.770_776delinsA). SD, stable disease. 
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